MHUA vs. TTOO, PAVM, GCTK, NEPH, PYPD, SSKN, NXGL, MBOT, LYRA, and PETV
Should you be buying Meihua International Medical Technologies stock or one of its competitors? The main competitors of Meihua International Medical Technologies include T2 Biosystems (TTOO), PAVmed (PAVM), GlucoTrack (GCTK), Nephros (NEPH), PolyPid (PYPD), STRATA Skin Sciences (SSKN), NEXGEL (NXGL), Microbot Medical (MBOT), Lyra Therapeutics (LYRA), and PetVivo (PETV). These companies are all part of the "surgical & medical instruments" industry.
T2 Biosystems (NASDAQ:TTOO) and Meihua International Medical Technologies (NASDAQ:MHUA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, institutional ownership, media sentiment, valuation and risk.
Meihua International Medical Technologies has a net margin of 0.00% compared to Meihua International Medical Technologies' net margin of -636.09%.
T2 Biosystems has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, Meihua International Medical Technologies has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.
23.2% of T2 Biosystems shares are owned by institutional investors. Comparatively, 1.2% of Meihua International Medical Technologies shares are owned by institutional investors. 0.1% of T2 Biosystems shares are owned by insiders. Comparatively, 66.6% of Meihua International Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Meihua International Medical Technologies has higher revenue and earnings than T2 Biosystems.
In the previous week, T2 Biosystems had 5 more articles in the media than Meihua International Medical Technologies. MarketBeat recorded 5 mentions for T2 Biosystems and 0 mentions for Meihua International Medical Technologies. T2 Biosystems' average media sentiment score of 1.43 beat Meihua International Medical Technologies' score of 0.40 indicating that Meihua International Medical Technologies is being referred to more favorably in the news media.
T2 Biosystems received 406 more outperform votes than Meihua International Medical Technologies when rated by MarketBeat users.
T2 Biosystems currently has a consensus target price of $3.00, indicating a potential downside of 46.81%. Given Meihua International Medical Technologies' higher probable upside, research analysts plainly believe T2 Biosystems is more favorable than Meihua International Medical Technologies.
Summary
Meihua International Medical Technologies beats T2 Biosystems on 7 of the 12 factors compared between the two stocks.
Get Meihua International Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for MHUA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MHUA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Meihua International Medical Technologies Competitors List
Related Companies and Tools
